Inici › Mieloma múltiple › Arizona › Phoenix
Assaigs clínics de Mieloma múltiple a Phoenix, AZ
16 estudis de Mieloma múltiple busquen participants en centres de Phoenix i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Mayo Clinic 1, Phoenix
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Mayo Clinic Phoenix, Phoenix
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
ReclutantFase 3
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutantFase 4
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutantFase 2
- Cancer Treatment Centers of America-Phoenix, Phoenix
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic Hospital in Arizona, Phoenix
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic Arizona, Phoenix
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutantFase 3
- Cancer Center at Saint Joseph's, Phoenix
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Phoenix
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutantFase 3
- Research Site, Phoenix
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- Mayo Clinic - Arizona, Phoenix
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Mayo Clinic Arizona /ID# 251405, Phoenix
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
ReclutantFase 3
- Cancer Center at Saint Joseph's, Phoenix
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutantFase 3
- Banner University Medical Center Tucson, University of Arizona, Phoenix
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
ReclutantFase 3
- GSK Investigational Site, Phoenix
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Phoenix
- Càncer de mama25 estudis
- Càncer colorrectal25 estudis
- Obesitat22 estudis
- Càncer de pulmó de cèl·lules no petites20 estudis
- Càncer metastàtic20 estudis
- Insuficiència cardíaca18 estudis
- Càncer de pròstata17 estudis
- Càncer (tots els tipus)17 estudis
- Càncer de pàncrees16 estudis
- Malaltia cardiovascular16 estudis
- Malaltia d'Alzheimer15 estudis
- Sobrepès15 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.